<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02902913</url>
  </required_header>
  <id_info>
    <org_study_id>617247</org_study_id>
    <nct_id>NCT02902913</nct_id>
  </id_info>
  <brief_title>Impact of Extra Virgin Olive Oil Oleocanthal Content on Platelet Reactivity</brief_title>
  <official_title>Impact of Extra Virgin Olive Oil Oleocanthal Content on Platelet Reactivity in Healthy Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>USDA, Western Human Nutrition Research Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Data from limited dietary intervention trials suggest that the cardiovascular health benefit
      of extra virgin olive oil (EVOO) may increase with phenolic content. However, while EVOOs
      contain an array of bioactive compounds, little information exists regarding the
      physiological effects of specific chemical species. Among the EVOO-derived phenolics with
      demonstrated anti-inflammatory effects in animal and in vitro models is oleocanthal, an
      inhibitor of cyclooxygenase (COX). The current study compared the impact of acute intake (40
      mL) of EVOO on platelet reactivity in healthy adult males (n=9). The volunteers were randomly
      assigned to consume three EVOOs in a double-blind controlled trial. The EVOO were
      characterized and chosen for equivalency in their total phenolic content and fatty acid
      profiles, but differing in their oleocanthal to oleacein ratio.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ten healthy adult males (20-50 years of age) will be enrolled into a randomized triple-blind,
      controlled crossover study that will test the acute effects of oleocanthal-rich extra virgin
      olive oil intake on platelet aggregation. Each participant will be asked to participate in
      four study days, separated by at least 1-week, in which they will be randomized to consume on
      each study day 40 mL (~3 tablespoons) of either oleocanthal-rich extra virgin olive oil (OO),
      or an extra virgin OO that is matched in total phenolics but oleocanthal-poor, or a refined
      OO that is low in all phenolics In addition to the oils, on a fourth study day visit, after
      completion of the study visits involving oil intake the subjects will be asked to take 400mg
      of ibuprofen.

      Collection procedures will be performed at the same time of the day to avoid circadian
      effects. A blood sample (50 mL ~ 3.5 tbsp) will be collected for the measurement of platelet
      aggregometry and COX metabolites. Following this initial blood draw, the subjects will
      consume their assigned test product for the day. Two-hours following the intake of the
      assigned olive oil, a second blood sample will be drawn (50 mL ~ 3.5 tbsp). After the second
      blood draw, the study day will be complete.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>All participants received all four interventions in a randomized, cross-over design in which both participant and caregiver were masked to the assignment (with the exception of the fourth intervention, ibuprofen, which was always administered at the final study visit).</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Optical Platelet Aggregometry</measure>
    <time_frame>Change from baseline 2 hours post intake</time_frame>
    <description>Maximal platelet aggregation in minutes will be measured using optical platelet aggregometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Activated Platelet Oxylipin Production</measure>
    <time_frame>Change from baseline 2 hours post intake</time_frame>
    <description>Oxylipins derived from cyclooxygenase, lipoxygenase, and cytochrome P450 dependent metabolism of AA were quantified using liquid chromatography with tandem mass spectrometry (LC-MS/MS) in 100 µL of PRP plasma activated with collagen or ADP as well as 100 µL of unactivated PRP plasma collected before and two hours after treatment with EVOO or ibuprofen.
Data were mean centered and reported as a % change from baseline.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Oleocanthal-rich, D2i2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oleocanthal-rich, D2i2 (Extra virgin olive oil containing oleocanthal to oleacein in a 2:1 ratio)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oleacein-rich, D2i0.5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oleacein-rich, D2i0.5 (Extra virgin olive oil containing oleocanthal to oleacein in a 1:2 ratio)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oleocanthal and Oleacein-low, D2i0</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oleocanthal and Oleacein-low, D2i0 (Extra virgin olive oil containing low amounts of oleocanthal to oleacein, but with a similar total phenolic content as the other two oils)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ibuprofen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ibuprofen, 400 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>D2i2</intervention_name>
    <description>Oleocanthal provided in a 2:1 ratio compared to oleacein</description>
    <arm_group_label>Oleocanthal-rich, D2i2</arm_group_label>
    <other_name>Oleocanthal-rich</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>D2i0.5</intervention_name>
    <description>Oleocanthal provided in a 1:2 ratio compared to oleacein</description>
    <arm_group_label>Oleacein-rich, D2i0.5</arm_group_label>
    <other_name>Oleocanthal-low</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>D2i0</intervention_name>
    <description>No oleocanthal and no oleacein</description>
    <arm_group_label>Oleocanthal and Oleacein-low, D2i0</arm_group_label>
    <other_name>Control EVOO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>400 mg of Ibuprofen</description>
    <arm_group_label>Ibuprofen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to comply with study protocols

          -  Willing to drink 2 tablespoons of olive oil

          -  BMI 18.5 to 30 kg/m2

          -  Weight ≥ 110 pounds

        Exclusion Criteria:

          -  Adults who are not able to consent

          -  BMI ≥ 31 kg/m2

          -  Under current medical supervision

          -  Self-reported daily use of drugs that are known to affect platelet function, such as
             aspirin, Excedrin, and NSAIDS

          -  Ibuprofen intolerance or allergy

          -  Cannot speak English

          -  Allergy to olives or olive oil

          -  Vegetarian, Vegan, food faddists, individuals using non-traditional diets, on a weight
             loss diet or individual following diets with significant deviations from the average
             diet of the general population.

          -  A history of cardiovascular disease, stroke, cancer, renal, hepatic, or thyroid
             disease, GI tract disorders, previous GI surgery

          -  Currently taking prescription drugs or supplements

          -  Indications of substance or alcohol abuse within the last 3 years

          -  Not willing to stop any supplement use, including herbal, plant or botanical, fish
             oil, oil supplements.

          -  Not willing to refrain from olive oil consumption.

          -  Blood Pressure ≥ 140/90 mmHg

          -  Self-reported malabsorption

          -  Metabolic panel results or complete blood counts that are outside of the normal
             reference range.

          -  Screening LDL ≥ 190 mg/dl for those who have 0 - 1 major risk factors apart from LDL
             cholesterol [(i.e. family history of premature coronary artery disease (male first
             degree relative &lt; 55 years; CHD in female first degree relative &lt; 65 years), cigarette
             smoker, HDL-C ≤ 40 mg/dL].

          -  Screening LDL ≥ 160 mg/dl for those who have 2 major risk factors apart from LDL
             cholesterol [(i.e. family history of premature coronary artery disease (male first
             degree relative &lt; 55 years; CHD in female first degree relative &lt; 65 years), cigarette
             smoker, HDL-C ≤ 40 mg/dL].

          -  Screening LDL ≥ than 130 mg/dl for those who have 2 major risk factors apart from LDL
             cholesterol ((i.e. family history of premature coronary artery disease (male first
             degree relative &lt; 55 years; CHD in female first degree relative &lt; 65 years), cigarette
             smoker, HDL-C ≤ 40 mg/dL), and a Framingham 10 - year Risk Score 10 - 20 % (using NCEP
             calculator).

          -  Current enrollee in a clinical research study.

          -  Individuals with blood clotting or platelet defect disorders
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roberta R Holt, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>September 7, 2016</study_first_submitted>
  <study_first_submitted_qc>September 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2016</study_first_posted>
  <results_first_submitted>July 26, 2018</results_first_submitted>
  <results_first_submitted_qc>October 18, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 7, 2019</results_first_posted>
  <last_update_submitted>October 18, 2019</last_update_submitted>
  <last_update_submitted_qc>October 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>platelet reactivity</keyword>
  <keyword>phenolic</keyword>
  <keyword>extra virgin olive oil</keyword>
  <keyword>cyclooxygenase</keyword>
  <keyword>oleocanthal</keyword>
  <keyword>oxylipin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>All Participants</title>
          <description>All participants received all four study interventions. The first three interventions were administered in random order:
Oleocanthal-rich, D2i2
Oleacein-rich, D2i0.5
Oleocanthal and Oleacein-low, D2i0
All participants received the last intervention, 400 mg of Ibuprofen, at the fourth (final) study visit.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>First Intervention (1 Day)</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Washout (7 Days)</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Second Intervention (1 Day)</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Washout (7 Days)</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Third Intervention (1 Day)</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Washout (7 Days)</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Ibuprofen (400mg)</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>All participants received all four study interventions. The first three interventions were administered in random order:
Oleocanthal-rich, D2i2
Oleacein-rich, D2i0.5
Oleocanthal and Oleacein-low, D2i0
All participants received the last intervention, 400 mg of Ibuprofen, at the fourth (final) study visit.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Optical Platelet Aggregometry</title>
        <description>Maximal platelet aggregation in minutes will be measured using optical platelet aggregometry</description>
        <time_frame>Change from baseline 2 hours post intake</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>All participants received all four study interventions. The first three interventions were administered in random order:
Oleocanthal-rich, D2i2
Oleacein-rich, D2i0.5
Oleocanthal and Oleacein-low, D2i0
All participants received the last intervention, 400 mg of Ibuprofen, at the fourth (final) study visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Optical Platelet Aggregometry</title>
          <description>Maximal platelet aggregation in minutes will be measured using optical platelet aggregometry</description>
          <units>percentage of maximal aggregation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>D2i2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13" spread="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D2i0.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35" spread="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D2i0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" spread="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ibuprofen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-57.5" spread="32.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Activated Platelet Oxylipin Production</title>
        <description>Oxylipins derived from cyclooxygenase, lipoxygenase, and cytochrome P450 dependent metabolism of AA were quantified using liquid chromatography with tandem mass spectrometry (LC-MS/MS) in 100 µL of PRP plasma activated with collagen or ADP as well as 100 µL of unactivated PRP plasma collected before and two hours after treatment with EVOO or ibuprofen.
Data were mean centered and reported as a % change from baseline.</description>
        <time_frame>Change from baseline 2 hours post intake</time_frame>
        <population>healthy adult males</population>
        <group_list>
          <group group_id="O1">
            <title>Oleocanthal-rich, D2i2</title>
            <description>Oleocanthal-rich, D2i2 (Extra virgin olive oil containing oleocanthal to oleacein in a 2:1 ratio)
D2i2: Oleocanthal provided in a 2:1 ratio compared to oleacein</description>
          </group>
          <group group_id="O2">
            <title>Oleacein-rich, D2i0.5</title>
            <description>Oleacein-rich, D2i0.5 (Extra virgin olive oil containing oleocanthal to oleacein in a 1:2 ratio)
D2i0.5: Oleocanthal provided in a 1:2 ratio compared to oleacein</description>
          </group>
          <group group_id="O3">
            <title>Oleocanthal and Oleacein-low, D2i0</title>
            <description>Oleocanthal and Oleacein-low, D2i0 (Extra virgin olive oil containing low amounts of oleocanthal to oleacein, but with a similar total phenolic content as the other two oils)
D2i0: No oleocanthal and no oleacein</description>
          </group>
          <group group_id="O4">
            <title>Ibuprofen</title>
            <description>Ibuprofen, 400 mg
Ibuprofen: 400 mg of Ibuprofen</description>
          </group>
        </group_list>
        <measure>
          <title>Activated Platelet Oxylipin Production</title>
          <description>Oxylipins derived from cyclooxygenase, lipoxygenase, and cytochrome P450 dependent metabolism of AA were quantified using liquid chromatography with tandem mass spectrometry (LC-MS/MS) in 100 µL of PRP plasma activated with collagen or ADP as well as 100 µL of unactivated PRP plasma collected before and two hours after treatment with EVOO or ibuprofen.
Data were mean centered and reported as a % change from baseline.</description>
          <population>healthy adult males</population>
          <units>percentage of change from baseline</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02"/>
                    <measurement group_id="O2" value="-0.45"/>
                    <measurement group_id="O3" value="-0.17"/>
                    <measurement group_id="O4" value="-0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>All Participants</title>
          <description>All participants received all four study interventions. The first three interventions were administered in random order:
Oleocanthal-rich, D2i2
Oleacein-rich, D2i0.5
Oleocanthal and Oleacein-low, D2i0
All participants received the last intervention, 400 mg of Ibuprofen, at the fourth (final) study visit.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Roberta R Holt</name_or_title>
      <organization>University of California, Davis</organization>
      <phone>530-752-4950</phone>
      <email>rrholt@ucdavis.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

